29th Nov 2007 10:51
Oxford Biomedica PLC29 November 2007 FOR IMMEDIATE RELEASE 29 NOVEMBER 2007 OXFORD BIOMEDICA WINS TECHMARK AWARD Oxford, UK: 29 November 2007: Oxford BioMedica (LSE: OXB), a leading genetherapy company, announced today that it has been presented with the techMARK2007 Achievement of the Year award for its collaboration with sanofi-aventis.The techMARK Awards, organised by the London Stock Exchange, are designed toreward outstanding achievement in the technology market. Professor AlanKingsman, Oxford BioMedica's Chief Executive Officer, collected the award lastnight during the ceremony held at the InterContinental Hotel in London. Oxford BioMedica announced its collaboration with sanofi-aventis in March 2007for the global development and commercialisation of TroVax(R), its novelimmunotherapy, for the treatment and prevention of cancers. Under the terms ofthis agreement, sanofi-aventis will pay Oxford BioMedica up to €518 million ifall development and registration targets are met for certain definedindications. Additional payments will be made if regulatory milestones areachieved in other cancer types. Oxford BioMedica is also entitled to escalatingroyalties on global sales of TroVax and to further undisclosed commercialmilestones when net sales of TroVax reach certain levels. Professor Kingsman commented: "The sanofi-aventis deal was a transformationalevent for Oxford BioMedica that provides both near and long-term value as wellas clear endorsement of our most advanced product. I am honoured to receive thisprestigious award. It is a testament to the achievement of the entire team atOxford BioMedica." -Ends- For further information, please contact:Oxford BioMedica plc: Tel: +44 (0)1865 783 000 Professor Alan Kingsman, Chief ExecutiveJPMorgan Cazenove Limited: Tel: +44 (0)20 7588 2828 James Mitford/Gina GibsonCity/Financial Enquiries: Tel: +44 (0)20 7466 5000 Lisa Baderoon/ Mark Court/ Mary-Jane Johnson BuchananCommunications Scientific/Trade Press Enquiries: Tel: +44 (0)20 7268 3002Gemma Price/ Holly Griffiths/ Katja StoutNorthbank Communications Notes to editors 1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment and commercialisation of novel therapeutic vaccines and gene-basedtherapies with a focus on oncology and neurotherapy. The Company was establishedin 1995 as a spin-out from Oxford University, and is listed on the London StockExchange. The Company has a platform of gene delivery technologies, which are based onhighly engineered viral systems. Oxford BioMedica also has in-house clinical,regulatory and manufacturing know-how. In oncology, the lead product candidateis TroVax(R), an immunotherapy for multiple solid cancers, which is licensed tosanofi-aventis for global development and commercialisation. A Phase III trialof TroVax in renal cancer is ongoing and two Phase III trials in colorectalcancer are planned. Oxford BioMedica has two other anti-cancer productcandidates in Phase II development for melanoma and pancreatic cancerrespectively. In neurotherapy, the Company has submitted a Clinical TrialApplication to start a Phase I/II trial of its gene-based treatment forParkinson's disease, ProSavin(R). The neurotherapy pipeline also includespreclinical gene-based therapeutics for vision loss, motor neuron disease andnerve repair. The Company is underpinned by over 80 patent families, which represent one ofthe broadest patent estates in the field. The Company has a staff ofapproximately 80 split between its main facilities in Oxford and its whollyowned subsidiary, BioMedica Inc, in San Diego, California. Corporate partnersinclude sanofi-aventis for TroVax and Wyeth for an anti-cancer targeted antibodytherapy. The Company also has collaborations with Sigma-Aldrich, MolMed andVirxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKlineand Pfizer. Further information is available at www.oxfordbiomedica.co.uk 2. techMARK Awards The annual techMARK Awards ceremony and dinner, hosted by the London StockExchange and sponsored by PricewaterhouseCoopers, is one of the largestgatherings of technology companies in the UK. It is the event to attend foranybody involved in the UK technology and life sciences markets. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica